Breaking News

MilliporeSigma, SystImmune Partner for Bi-specific Antibody Development

CHOZN expression system to be used to accelerate development timelines

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MilliporeSigma said that its CHOZN expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic. The CHOZN expression system is designed to deliver manufacturing-ready robust and stable producing clones with a workflow that minimizes the resources needed to complete a cell line development project. As a result, users are able to quickly evaluate more molecules in their pipeline. “When compared with alt...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters